Table 1. Clinical features of patients’ cohort.
| Variable | Cohort Distribution (quartiles) | ||||
|---|---|---|---|---|---|
| Q1 | Q2 | Q3 | Smallest | Largest | |
| Age | 23 | 25 | 27 | 21 | 39 |
| Height (cm) | 163 | 169 | 175 | 157 | 184 |
| Weight (kg) | 63 | 67.5 | 78 | 55 | 115 |
| BMI1 | 22.5 | 24.4 | 26.5 | 18.9 | 34.7 |
| Evolution time2 | 16 | 32 | 48 | 10 | 192 |
| Time for treatment3 (weeks) | 5 | 8 | 12 | 3 | 60 |
| Time from end of treatment 4 (weeks) | 6.5 | 23 | 31 | 0** | 113 |
| Lesion area (cm2) | 4.4 | 7.5 | 12 | 1.68 | 190* |
| Haemoglobin | 15.6 | 16 | 16.9 | 13.7 | 17.6 |
| White blood cells counting | 6,070 | 7,500 | 8,700 | 4,000 | 11,310 |
| Platelets | 247,500 | 290,500 | 323,500 | 200,000 | 393,000 |
| Lymphocyte (%) | 25 | 33 | 43 | 12 | 58 |
| Neutrophil (%) | 46 | 50 | 60 | 23 | 72 |
| Eosinophil (%) | 2.8 | 4.5 | 6.6 | 1.2 | 12 |
1 Body mass index
2 Time (in weeks) between date of diagnosis confirmation and date of patient recruitment for the study
3 Elapsed time between the onset of symptoms and initiation of treatment with Glucantime
4 Time (in weeks) between date of treatment end and date of patient recruitment for the study
*Highest value corresponds to a lesion of 20 weeks of evolution on the right leg of a patient who presented multiple lesions and a BMI of 30.47
** Corresponding to a patient that was just ending the treatment without response during the time of the study recruitment